Stockscreener 앱 받기
4.52
0.44%
-0.02
전일 마감가:
$4.54
열려 있는:
$4.54
하루 거래량:
625.67K
Relative Volume:
0.34
시가총액:
$631.28M
수익:
$7.83M
순이익/손실:
$-64.92M
주가수익비율:
-8.5331
EPS:
-0.5297
순현금흐름:
$-47.22M
1주 성능:
+0.00%
1개월 성능:
+2.96%
6개월 성능:
+80.08%
1년 성능:
+258.73%
1일 변동 폭
$4.495
$4.60
1주일 범위
$4.23
$4.62
52주 변동 폭
$1.22
$5.15
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
4.52 | 634.07M | 7.83M | -64.92M | -47.22M | -0.5297 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 개시 | Oppenheimer | Outperform |
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics (ACRS) price target increased by 12.65% to 9.64 - MSN
Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - The Chronicle-Journal
Aclaris Expands Immunology Pipeline Ahead of Key Trial Data - MyChesCo
ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding - TradingView
ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026 - TradingView
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
MSN Money - MSN
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Stifel raises Aclaris Therapeutics price target to $4 on pipeline By Investing.com - Investing.com Nigeria
Stifel raises Aclaris Therapeutics price target to $4 on pipeline - Investing.com
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - The Manila Times
Aclaris: Q1 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (NASDAQ: ACRS) deepens loss while boosting R&D - Stock Titan
Aclaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Investing News Network
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Moomoo
Aclaris (NASDAQ: ACRS) posts Q1 2026 loss but boosts cash runway - Stock Titan
Aclaris says cash lasts through 2028 with key skin, asthma data due - Stock Titan
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Guggenheim initiates coverage of Aclaris Therapeutics (ACRS) with buy recommendation - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Guggenheim - MarketBeat
Aclaris (ACRS) CMO vesting 36,375 RSUs with 9,330 shares tax withheld - Stock Titan
Guggenheim Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $12 - Moomoo
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Aclaris Reports Phase 1a Results for ATI-052, Advances Pipeline - MyChesCo
Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth - Yahoo Finance
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody CandidatesSlideshow (NASDAQ:ACRS) 2026-04-28 - Seeking Alpha
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus - MarketBeat
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4R? Bispecific Antibody, and Announces Lichen Planus as Lead Indication f - Investing News Network
Aclaris Posts Strong Phase 1a ATI-052 Data, Sets Lichen Planus As Lead Indication For ATI-2138 - RTTNews
Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055 - marketscreener.com
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):